Autopsy reveals uneven brain clearance by Alzheimer's drug
A JAMA postmortem case study of a patient treated with aducanumab shows amyloid-beta plaques were cleared in some brain regions but persisted in others, suggesting uneven drug penetration and challenging the idea that removing amyloid always yields cognitive benefits. Some regions with reduced amyloid also had fewer tau tangles and slower atrophy, hinting at possible regional effects, but overall evidence for clinical improvement remains uncertain and ongoing trials are investigating whether earlier treatment could help.
